Are peptides safe long-term, or do we just not know yet?

There is no single long-term safety answer for “peptides.” Some approved medicines have large trials and ongoing surveillance; many experimental products have little meaningful follow-up in humans. SELECT followed 17,604 people with existing cardiovascular disease and overweight or obesity, without diabetes, for an average of about 40 months. Semaglutide reduced major cardiovascular events in that population, while adverse events also led more participants to stop treatment than with placebo.[1]

That is substantial evidence, but it is neither lifetime observation nor proof of safety for every person or every peptide. Trial duration, participant age, underlying illness, and the outcomes actively monitored all affect what can be concluded. Rare harms or problems after many years may require postmarketing monitoring. An absence of serious events in a small, short study cannot exclude them.[2]

For experimental products such as BPC-157 and CJC-1295, the human safety evidence is much less developed. Product quality adds a separate uncertainty beyond the molecule’s biological effects. The honest conclusion is molecule-specific: some treatments have a reasonably characterized benefit-risk balance for defined patients, while others still lack the data needed to estimate long-term risk reliably.[3]